Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Croda International ( (GB:CRDA) ) has shared an announcement.
Croda reported 2025 sales of £1.7bn, up 6.6% at constant currency, with Consumer Care and Life Sciences both delivering higher sales, margins and profits, while Industrial Specialties declined. Adjusted operating profit rose 7.9% at constant currency to £295.3m, though statutory profit was hit by over £100m of impairment and restructuring charges tied to optimising lipids capacity, as the group sharpened its portfolio.
The company said its transformation programme is ahead of plan, realising £28m of gross benefits in 2025 and launching a working capital initiative, while leverage fell and the dividend was nudged higher. Management set a new 2026–28 financial framework targeting 3–6% organic sales CAGR, an operating margin above 20%, stronger cash generation and higher returns on capital, signalling confidence that efficiency gains, focused innovation and better customer experience will underpin improved performance despite uncertain markets.
The most recent analyst rating on (GB:CRDA) stock is a Buy with a £31.50 price target. To see the full list of analyst forecasts on Croda International stock, see the GB:CRDA Stock Forecast page.
Spark’s Take on GB:CRDA Stock
According to Spark, TipRanks’ AI Analyst, GB:CRDA is a Neutral.
Croda International’s overall stock score reflects a mix of solid financial health and strategic initiatives, tempered by valuation concerns and technical weaknesses. The company’s strong earnings call and positive corporate events provide a supportive backdrop, but investors should be cautious of the high P/E ratio and bearish technical indicators.
To see Spark’s full report on GB:CRDA stock, click here.
More about Croda International
Croda International is a UK-based specialty chemicals group that uses “smart science” to develop high-performance ingredients and solutions for consumer care, life sciences and industrial markets. Its portfolio spans beauty and personal care actives, fragrances, home care, crop protection, seed enhancement and pharmaceutical ingredients, with a strategic focus on higher-growth, value-added applications globally.
Average Trading Volume: 555,082
Technical Sentiment Signal: Sell
Current Market Cap: £4.15B
For detailed information about CRDA stock, go to TipRanks’ Stock Analysis page.